Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2021 · 10-Q
Revenue$59.69M$59.69M+42.6% vs Q3 2020 Net Income$13.72M$13.72MN/M vs Q3 2020 EPS Diluted$0.80$0.80N/M vs Q3 2020 Operating Income$15,706,000+319.2% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$18,253,000+70.5% Margins · derivedOperating margin26.3%+17.4 pt vs Q3 2020
Net margin23.0%+39.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 9, 2021 · 40 d after period end